EN PL
 
EN PL
Bieżący numer
Archiwum
Online first
O czasopiśmie
Dla autorów
Książki i Konferencje
3/2016 vol. 54
Pobierz cytowanie
KRÓTKIE DONIESIENIE
Rivaroxaban - safe therapeutic option in patients with antiphospholipid syndrome? Own experience in 23 cases.
Ewa Haładyj
,
 
Marzena Olesińska
 
 
 
Więcej
Ukryj
 
Data nadesłania: 12-04-2016
 
 
Data ostatniej rewizji: 23-05-2016
 
 
Data akceptacji: 07-06-2016
 
 
Data publikacji online: 18-07-2016
 
 
Data publikacji: 30-06-2016
 
 
Reumatologia 2016;54(3):146-149
DOI: https://doi.org/10.5114/reum.2016.61217
 
 
Artykuł (PDF)
Referencje (19)
 
SŁOWA KLUCZOWE
antiphospholipid syndrome
rivaroxaban
warfarin
thrombosis
 
DZIEDZINY
SLE, zespół Sjögrena i zespół antyfosfolipidowy - etiologia, patogeneza, obraz kliniczny i leczenie
 
STRESZCZENIE
In the therapeutic approach to patients with antiphospholipid syndrome (APS) with thrombotic manifestations, oral vitamin K antagonists (VKA) remain the standard of care. However, the use of VKA is very often associated with inability to achieve a therapeutic dose even in patients maintaining nutritional and therapeutic restrictions. The non-vitamin-K oral anticoagulants (NOAC) have a lot of advantages, but their efficacy and safety in APS have not been proven. We present 23 patients with APS treated with rivaroxaban in our department. Recurrence of thrombosis was observed only in 1 patient. No major or minor bleeding occurred. It proves the efficacy of treatment with rivaroxaban, but our observations require further prospective, randomized studies.
 
REFERENCJE (19)
1.
Della Valle P, Crippa L, Safa O, et al. Potential failure of the International Normalized Ratio (INR) system in the monitoring of oral anticoagulation in patients with lupus anticoagulants. Ann Med Interne 1996; 147 (Suppl. 1): 10-14.
Google Scholar
 
 
2.
Chighizola CB, Moia M, Meroni PL. New oral anticoagulants in thrombotic antiphospholipid syndrome. Lupus 2014; 23: 1279-1282.
Google Scholar
 
 
3.
Erkan D, Aguiar CL, Andrade D, et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014; 13: 685-696.
Google Scholar
 
 
4.
Cohen H, Machin SJ. Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants? Lupus 2010; 19: 486-491.
Google Scholar
 
 
5.
Signorelli F, Nogueira F, Domingues V, et al. Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. Clin Rheumatol 2016; 35: 801-805.
Google Scholar
 
 
6.
Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
Google Scholar
 
 
7.
The EINSTEIN-PE Investigators. Büller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
Google Scholar
 
 
8.
Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
Google Scholar
 
 
9.
Pengo V, Banzato A, Bison E, et al. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. Lupus 2016; 25: 301-306.
Google Scholar
 
 
10.
Cohen H, Doré CJ, Clawson S, et al.; RAPS Trial Protocol Collaborators. Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. Lupus 2015; 24: 1087-1094.
Google Scholar
 
 
11.
Son M, Wypasek E, Celinska-Lowenhoff M, Undas A. The use of rivaroxaban in patients with antiphospholipid syndrome: A series of 12 cases. Thromb Res 2015; 135: 1035-1036.
Google Scholar
 
 
12.
Sciascia S, Breen K, Hunt BJ. Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism. Blood Coagul Fibrinolysis 2015; 26: 476-477. Erra­tum in: Blood Coagul Fibrinolysis 2015; 26: 597.
Google Scholar
 
 
13.
Agnelli G, Becattini C, Franco L. New oral anticoagulants for the treatment of venous thromboembolism. Best Pract Res Clin Haematol 2013; 26: 151-161.
Google Scholar
 
 
14.
Erkan D, Aguiar CL, Andrade D, et al. 14th international congresson antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014; 13: 685-696.
Google Scholar
 
 
15.
Schaefer JK, McBane RD, Black DF, et al. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost 2014; 112: 947-950.
Google Scholar
 
 
16.
Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010; 376: 1498-1509.
Google Scholar
 
 
17.
Win K, Rodgers GM. New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol 2014; 89: 1017.
Google Scholar
 
 
18.
Noel N, Dutasta F, Costedoat-Chalumeau N, et al. Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmun Rev 2015; 14: 680-685.
Google Scholar
 
 
19.
Peterson LK, Willis R, Harris EN, et al. Antibodies to Phosphatidylserine/Prothrombin Complex in Antiphospholipid Syndrome: Analytical and Clinical Perspectives. Adv Clin Chem 2016; 73: 1-28.
Google Scholar
 
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Udostępnij
Wyślij mailem
ARTYKUŁ POWIĄZANY
Antiphospholipid antibodies in patients with systemic lupus erythematosus – diagnostic significance and clinical implications. Own observations
Health-related quality of life impairment is equal for antiphospholipid syndrome whether primary or associated with systemic lupus erythematosus
ARTYKUŁ PRZEGLĄDOWY/REVIEW PAPER
Ocena przydatności różnych przeciwciał antyfosfolipidowych w diagnostyce wtórnego zespołu antyfosfolipidowego w przebiegu tocznia rumieniowatego układowego – przegląd literatury i obserwacje własne
ARTYKUŁ ORYGINALNY
Charakterystyka chorych na reumatoidalne zapalenie stawów z obecnymi przeciwciałami antyfosfolipidowymi
Opis przypadku
Wtórny zespól antyfosfolipidowy spowodowany nierozpoznanym zespołem nabytego niedoboru odporności. Opis przypadku
Indeksy
 
Indeks słów kluczowych
Indeks dziedzin
Indeks autorów
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
© 2006-2024 Journal hosting platform by Bentus
Scroll to top